HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Facts, not fear, should guide decisions about contralateral prophylactic mastectomy
• AACR receives PHL Life Sciences Ultimate Solution Award
• AACR report: Sustained federal commitment required to accelerate cancer research progress
• ASH to present Henry M. Stratton Medal to two senior investigators
• Atezolizumab improves OS in advanced NSCLC, regardless of PD-L1 status
• Biden announces steps to improve clinical trials under cancer moonshot
• Ceritinib improves PFS in patients with ALK–positive NSCLC
• City of Hope announces faculty appointments
• Fox Chase Cancer Center announces faculty appointments
• Investigators receive grants for bavituximab research
• Maryland Proton Treatment Center appoints medical director
• Memorial Sloan Kettering program designed to meet needs of teens, young adults with cancer
• Moffitt Cancer Center names malignant hematology department chair
• Selinexor plus dexamethasone appears active in heavily pretreated myeloma
• Senate committee weighs in on laboratory developed test regulation
• Summit Medical Group MD Anderson Cancer Center names chief of oncology
• Trial of MST-188 in sickle cell disease fails to meet primary endpoint
• University of Michigan Comprehensive Cancer Center appoints director
• Animal Farm, 1984 and The Hunger Games Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA accepts investigational new drug application for cantrixil to treat ovarian cancer
• FDA changes dosing regimen for Opdivo in three approved indications
• FDA grants breakthrough therapy designation to SL-401
• FDA grants fast track designation to niraparib for ovarian cancer
• FDA grants orphan drug designation to SB-FIX for hemophilia B
• FDA grants orphan drug designation to ZW25 and ZW33 for ovarian cancer treatment
• FDA grants priority review to rucaparib for advanced BRCA–mutated ovarian cancer
• FDA recommends Zika testing for all US blood donations
• FDA warns patients, physicians against using ovarian cancer screening tests
• ODAC: Qapzola does not effectively treat nonmuscle-invasive bladder cancer
• Proposed legislation may provide some relief for frustrated physicians
• Adjuvant radiation use persists among elderly women with stage I, ER-positive breast cancer
• CD19 CAR T cells induce high response rate in advanced ALL
• Ceritinib effectively treats ALK–rearranged NSCLC
• Diabetes drug pioglitazone increases risk for bladder cancer
• Genetic testing has increased in young women with breast cancer
• High daily intake of sweetened beverages, sucrose increase risk for biliary tract cancer
• In vitro fertilization not associated with increased risk for breast cancer
• Increased travel distance linked to lower radiation receipt for rectal cancer
• Interim PET-CT may safely guide adapted treatment for Hodgkin lymphoma
• Ipilimumab plus T-VEC shows promise for metastatic melanoma
• Metastatic site affects advanced prostate cancer survival
• Metformin may act as a protective agent against colorectal cancer
• Minimal residual disease status correlates with PFS in CLL
• Minimally invasive hysterectomy safe, effective for women with endometrial cancer
• Most hematologic oncologists accept standard quality end-of-life measures
• New app would increase PCP awareness of sickle cell guidelines, help connect with specialists
• NSCLC tumor markers linked to decreased overall survival
• Overdiagnosis accounts for increased thyroid cancer incidence
• Overweight, obesity risk factors for cardiotoxicity from anthracyclines, trastuzumab
• Pediatric melanomas mimic benign skin lesions
• Plasma analysis shows promise for NSCLC T790M genotyping
• Postoperative radiotherapy deferral on the rise in pediatric medulloblastoma
• Prelabor cesarean delivery may increase risk for childhood ALL
• Premorbid obesity adversely affects pancreatic cancer mortality rates
• President Obama outlines progress, future of Affordable Care Act
• Prolonged nightly fasting may reduce breast cancer recurrence risk
• Standard neoadjuvant chemoradiotherapy underused for advanced rectal cancer
• Statin use linked to decreased risk for recurrent venous thrombosis
• Study links RAI dose, second primary malignancy in thyroid cancer
• Tasquinimod prolongs radiographic PFS, not OS, in metastatic prostate cancer
• Training, collaboration key to overcoming ‘inadequacies of care’ for sickle cell disease
• Tumor profiling may predict response to anti–PD-1 therapy for metastatic melanoma
• Ultrasound comparable to mammography for breast cancer detection
• Weekly paclitaxel fails to prolong PFS in ovarian cancer
• ACA has improved cancer care, clinical trial access among Hispanics
• Adoption of stereotactic body radiation therapy improves OS in elderly patients with NSCLC
• Androgen receptor expression uncommon in black women with triple-negative breast cancer
• Financial burdens more common in black cancer survivors
• Late toxicity comparable between extremely hypofractionated, conventional radiotherapy for prostate cancer
• Postoperative stereotactic radiosurgery may represent new standard of care for brain metastases
• Telephone helpline increases access to cancer prevention, control programs
• Should women be required to meet specific risk criteria to undergo contralateral prophylactic mastectomy?